Low-dose adriamycin remission maintenance for advanced acute lymphoblastic leukemia: a Southwest Oncology, Group study.

Abstract

A low-dose maintenance schedule of adriamycin was evaluated in children with advanced acute lymphoblastic leukemia. Thirty-six evaluable patients who achieved two or more remissions were given adriamycin, 10 mg/m2/week, as a single maintenance agent. The median duration of second remission was 17 weeks, but only 5 weeks for third and fourth remission. Although the therapy was not found effective in more advanced disease, the median duration of second remission approached that obtained from various multi-agent treatment schedules. We conclude that the therapeutic efficacy of this treatment schedule makes it appealing for incorporation into multi-drug combination regimens.

• Authors: E Hvizdala, D Komp, A Ragab, W Crist, J Y Chu
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 9 Issue 5 Pg. 477-82 ( 1981) ISSN: 0098-1532 [Print] United States
• PMID: 7029239 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Doxorubicin

Topics

• Adolescent
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Doxorubicin (administration & dosage, adverse effects)
• Drug Administration Schedule
• Humans
• Leukemia, Lymphoid (drug therapy)